title: Advances in the management of chronic obstructive pulmonary disease.
abstract: Chronic obstructive pulmonary disease (COPD) is a progressive and irreversible airflow limitation with extreme economic and social burden. It is estimated that over the next two decades, it will become the 5(th) most prevalent disease and the 3(rd) most common cause of death in the world. A better understanding of the pathogenesis of airway inflammation and alveolar destruction allows for the development of new therapeutic targets. Tobacco smoking is the most important risk factor in the development of COPD, thus making smoking cessation of the outermost importance. This article provides a critical review of present therapy for COPD. In addition to conventional treatment (bronchodilators, corticosteroids and antibiotics) and smoking cessation therapies, novel approaches with potential benefit are discussed.
authors.affiliation: Medical Service, Pulmonary Section, Veterans Affairs Palo Alto Healthcare System, USA. ziedalski@stanford.edu
authors.forename: Tomasz M
authors.initials: TM
authors.lastname: Ziedalski
authors.forename: Viji
authors.initials: V
authors.lastname: Sankaranarayanan
authors.forename: Rajinder K
authors.initials: RK
authors.lastname: Chitkara
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D015995:Prevalence; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000209:etiology / Q000401:mortality; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects*; D016540:Smoking Cessation
chemical_list: D000305:Adrenal Cortex Hormones; D001993:Bronchodilator Agents